Key result
Congenital dysfibrinogenemia is linked to thrombosis rates ~7-fold higher than major bleeding.
Cohort (n=101)
Yes
Answers are grounded in this paper and cite their sources.
We conducted a multicenter study of 101 patients with congenital dysfibrinogenemia (CD) to characterize the incidence of hemorrhagic and thrombotic events as well as complications of pregnancy and surgery. At the time of diagnosis, 10.9% and 13.9% had experienced major bleeding and thrombotic events, respectively. During a mean follow-up of 8.8 years after CD diagnosis, the incidence of major bleeding and thrombotic events was 2.5 and 18.7 per 1000 patient-years, respectively, with estimated cumulative incidences at age 50 years of 19.2% and 30.1%. We identified 111 pregnancies with an overall incidence of spontaneous abortions and postpartum hemorrhage of 19.8% and 21.4%, respectively. The risk of postpartum hemorrhage was associated with a previously identified bleeding phenotype (odds ratio, 5.8; 95% CI, 1.2 to 28.0). Among 137 surgical procedures analyzed, 9 (6.5%) were complicated by abnormal bleeding. Propositi vs relatives, sex, mutation hotspots, fibrinogen levels, and activity:antigen ratios were not associated with the risk of thrombotic or bleeding outcomes. In conclusion, the results of our study, the largest in genotyped CD and the first including long-term history, indicate that propositi with CD and their relatives carry not only a high risk of major bleeding, including postpartum hemorrhage, but also of thrombotic event.
No takes yet. Share an insight, caveat, or question.
Casini et al. (2014) conducted a cohort in Congenital dysfibrinogenemia (n=101). Congenital dysfibrinogenemia was evaluated on Major bleeding and thrombotic events. Congenital dysfibrinogenemia was associated with an incidence of major bleeding and thrombotic events of 2.5 and 18.7 per 1000 patient-years, respectively.
Synapse has enriched 10 related papers. Consider them for comparative context: